Tanarra Capital
VC Fund
Melbourne, Australia
Tanarra Capital is a VC fund in Melbourne focused on Artificial Intelligence and Medical. Tanarra is an Australian family office investment and advisory firm. Tanarra invests in a wide range of early-stage ventures, private and public companies in Australia and around the world. Current early-stage investments include Pexip, a world-leading video technology company based in Oslo; Genomics, an Oxford-based business using geneticanalysis to improve pharma R&D investment returns; and Oxford PV, a new generation solar photovoltaic cell technology. Previous investments have included Business Spectator, the business media publication founded by well-known Australian journalist Alan Kohler, which was later acquired by News Corporation.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
- Fund size:
- $217M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Tanarra Capital invests in
Stages Tanarra Capital invests in
Countries Tanarra Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3.7M–$7.9M
- Series A
- $9.3M–$13M
- Series B
- $9.1M–$33M
Investment Focus
Industry
- Artificial Intelligence 3 (30%)
- Medical 2 (20%)
- Robotics 2 (20%)
- Software 2 (20%)
- Biopharma 2 (20%)
Stage
- Seed 3 (30%)
- Series A 2 (20%)
- Series B 2 (20%)
- Pre-Seed 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- United Kingdom 5 (50%)
- Hong Kong 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Wylie
CEO and Founder
|
CEO and Founder | Total investments: 0 | Find email | |
Maja Sliwinski
Investment Director
|
Investment Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment | $30M / Series B / May 21, 2026 | ||
| OXECO designs, develops and manufactures surface treatments for composites and engineering plastics. | $10.5M / Venture - Series Unknown / Jun 07, 2022 | ||
| August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment | $9.3M / Series A / Sep 10, 2020 | ||
| Fraction is a dynamic and rapidly growing company. | Seed / Jan 01, 2020 | ||
| Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. | $9.1M / Series B / Dec 09, 2018 | ||
| At Animal Dynamics they know that nature’s evolved designs are more efficient, elegant and powerful than anything yet built by man. However, the last decade has seen revolutions in analytical technology that allow us to evaluate high-performance animals to a previously unachievable degree, and use cutting-edge science to understand the fundamentalmechanisms underlying this performance.AD does not simply attempt to replicate the high-performance natural designs, but marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from their environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering. | $7.9M / Seed / Oct 09, 2018 | ||
| Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. | $32.5M / Series B / Aug 30, 2018 | ||
| August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment | $3.7M / Seed / Jun 20, 2018 | ||
| Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic. | $900K / Pre-Seed / Jun 01, 2018 | ||
| Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. | $13.4M / Series A / May 22, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tanarra Capital invest in?
Tanarra Capital invests primarily in Artificial Intelligence, Medical and Robotics startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Tanarra Capital invest in?
Tanarra Capital typically joins rounds of $3.7M–$7.9M at Seed, $9.3M–$13M at Series A and $9.1M–$33M at Series B. These are whole funding-round sizes, not Tanarra Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Tanarra Capital took part in.
How do I contact Tanarra Capital?
Public channels for Tanarra Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tanarra Capital?
The team at Tanarra Capital includes John Wylie (CEO and Founder) and Maja Sliwinski (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
